Atea Pharmaceuticals
Drug development and COVID 19 issues involving FDA, DOD, HHS, and OWS
Based in MA
🤖
AI Overview
With $160K in lobbying spend across 18 quarterly filings, Atea Pharmaceuticals is an active lobbying client. Their lobbying covers 1 issue area. Active from 2020 to 2024.
$160K
Total Spend
5
Years Active
1
Firms Hired
1
Lobbyists Deployed
1
Issues Lobbied
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2020 | $60K |
| 2021 | $70K |
| 2022 | $30K |
| 2023 | $0 |
| 2024 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
- •Covid-19 Drug development involving DOD, HHS, FDA, and OWS
- •Drug Development for COVID
- •Covid treatment issues
Related Analysis
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Healthcare's $3 Billion Bet
The healthcare industry's massive lobbying investment.
Federal Lobbying Statistics 2025
The definitive stats — $37.7B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.